Please ensure Javascript is enabled for purposes of website accessibility

3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street

By Cory Renauer – Aug 30, 2021 at 6:36AM

Key Points

  • Wall Street analysts watching a real estate stock that's been disappointing investors with losses think it could bounce right back.
  • A diagnostics company using artificial intelligence to lower the cost of treating kidney disease is looking awfully cheap to the analysts who follow it.
  • Analysts are more than a little enthusiastic about an innovative medical-device company that could prevent heaps of hospital visits.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.

The stock market's been blasting through its all-time highs left and right lately. If a soaring stock market has you thinking all the good stocks out there are overpriced, I've got good news from Wall Street.

All three of these high-growth stocks have consensus price targets on them that suggest they're undervalued by 30% or more. Here's why the investment bank analysts who get paid to understand these businesses say their stock prices are way too low right now. 

Three investors sitting at a table.

Image source: Getty Images.

1. Redfin

Redfin (RDFN 1.16%) shares have tumbled a frightening 48% from their peak this February. Wall Street analysts are expecting the real estate stock to bounce back stronger than ever, though. The consensus price target on Redfin at the moment is 30% higher than where it sits now.

The stock has given up much of 2020's gains thanks to a housing market that's been more difficult than usual. While investors cheered for Redfin's profits last year, they're extremely nervous about the losses it's posting in 2021.

The current housing shortage has led to such a tight market that it makes Redfin's lucrative iBuyer service unappealing. The situation has dragged on longer than expected, but the shortage is temporary. Investors can rest easily knowing there's plenty of cash on the balance sheet to see the company through this tough time. 

Redfin's laying down some rubber to support a high-growth strategy, but it isn't spinning its wheels. In the first half of 2021, the company reported a gross profit that rose 186% year over year to a level that was significantly higher than operating expenses recorded in the previous year period. It's probably just a matter of time before this fast-growing company begins producing a strong and sustainable profit.

2. Renalytix

Renalytix (RNLX 3.31%) shares are up around 69% since the beginning of the year. Analysts on Wall Street and beyond think it can go a whole lot higher, too. The consensus price target for Renalytix suggests a 30% gain over recent prices.

Shares of Renalytix have been soaring because it looks as if its chronic-kidney-disease test, KidneyIntelX, can rapidly expand into its healthcare niche. The test employs machine learning techniques to predict which chronic-kidney-disease patients are most likely to progress. 

Pricy treatment can prevent bad kidneys from getting worse, but not everyone needs costly intervention to keep off a transplant waiting list. Renalytix recently published results of a budget impact analysis that suggests healthcare plan sponsors can save around $220 per chronic-kidney-disease patient per year by monitoring patients with KidneyIntelX instead of just standard kidney failure detection methods.

According to the CDC, around 37 million Americans have chronic kidney disease. With hard data that proves it can lower America's enormous healthcare bills, a large portion of this group could end up receiving KidneyIntelX tests on a regular basis.

Physician at work.

Image source: Getty Images.

3. Inari Medical

Inari Medical (NARI -0.99%) shares are down around 34% since they peaked in April. Wall Street analysts appear fairly confident that a swift rebound is in the cards. The consensus price target for Inari Medical represents a 47% premium over its price at the moment.

Inari Medical sells a proprietary new clot-removal device. Sales are growing fast, but not quite as quickly as investors had expected. Despite the recent drop in share price, the stock still trades at a high price-to-sales multiple of 21.5 times trailing revenue. 

The company reported an 11% sequential gain in the second quarter that suggests a slowdown when you consider sales grew 150% year over year. Severe COVID-19 patients are a significant source of revenue for Inari Medical right now, but this well is rapidly drying up.

I think the recent loss is a bargain purchase opportunity. Clot removal procedures performed with Inari Medical's devices are changing the way hospitals treat dangerous blood clots. Getting patients out of beds quickly, and safely, helps hospitals' bottom lines immensely. With this in mind, we can reasonably expect Inari Medical to grow into its seemingly high valuation and then some. 

Cory Renauer owns shares of Renalytix. The Motley Fool owns shares of and recommends Redfin. The Motley Fool recommends the following options: short August 2021 $65 puts on Redfin. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inari Medical, Inc. Stock Quote
Inari Medical, Inc.
NARI
$75.00 (-0.99%) $0.75
Redfin Stock Quote
Redfin
RDFN
$5.23 (1.16%) $0.06
Renalytix AI plc Stock Quote
Renalytix AI plc
RNLX
$1.56 (3.31%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.